(NASDAQ: ANAB) Anaptysbio's forecast annual revenue growth rate of 1.31% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Anaptysbio's revenue in 2025 is $111,872,000.On average, 6 Wall Street analysts forecast ANAB's revenue for 2025 to be $1,993,789,839, with the lowest ANAB revenue forecast at $815,896,374, and the highest ANAB revenue forecast at $2,726,510,029. On average, 5 Wall Street analysts forecast ANAB's revenue for 2026 to be $3,542,994,013, with the lowest ANAB revenue forecast at $352,565,952, and the highest ANAB revenue forecast at $6,052,382,176.
In 2027, ANAB is forecast to generate $2,985,205,296 in revenue, with the lowest revenue forecast at $2,203,537,200 and the highest revenue forecast at $4,260,171,920.